

unlocking the potential of ultrasound





# 50 million

medical professionals in the world





This is why ultrasound remains a specialist skill, practised by only 2% of medical professionals

Our aim is to not only

# help the 2%

but to unlock the

98%


# Our range of intelligent ultrasound products



aims to unlock ultrasound for all medical professionals

# In October 2017 we organised into two divisions







# **SIMULATION DIVISION**



# The gold standard in ultrasound training simulators:













**LAUNCHED FEB '18** 

Echocardiography simulator range aimed at teaching cardiology and anaesthesiology schools

New hybrid version of ScanTrainer and HeartWorks aimed at the Emergency market





medical schools and hospitals globally











# **Simulation Division - Territory Review**







# **CLINICAL DIVISION**



# Automated image analysis using Al





GUIDING





- >350,000 graded obstetric images
- Guides, supports + 100% audit trail
- First pilot in UK hospital

- Augmented Reality based needling assistant
  - Working POC device
  - Patent filed
  - C. £500k Innovate UK grant won


**DEVELOPMENT STARTED** 

Innovate UK



#### **FIRST PILOT IN UK HOSPITAL**










# **Automated GP and home scanning**



# MedaPhor product development pathway





#### **SIMULATION**









#### **DEEP LEARNING**







Automated image analysis and real-time quality guidance

# AUGMENTED REALITY



Ultrasound needle guidance



**ARTIFICIAL** 

INTELLIGENCE

Automated diagnostic triaging device\*



NEEDLEGUIDE

£4.2m sales in 2017

SCANTRAINER®

**LAUNCHED** 

PILOT IN UK HOSPITAL

**INNOVATE WON** 

MedaPhor aim's to be the first company in the world to link training and on-going clinical ultrasound performance

### LOCAL



#### LIVE SCANNING SUPPORT AND AUDIT







# CENTRAL

#### STUCTURED TRAINING



#### **OBJECTIVE ASSESSMENT**




#### **100% CLINICAL AUDIT**







Our unique combination of



can unlock the potential of ultrasound for all medical professionals



# **2017 FINANCIALS**

### **2017 FINANCIAL RESULTS**



### **Summary**

- Increased 27% to £4.2m (2016: £3.3m)
- Raised £5.4m net of costs by way of placing of shares
- Acquired Intelligent Ultrasound Limited for £3m
- £1.3m Increase in overheads explained by acquisitions and amortisation of intangibles
- Exceptional items in the year of £2.9m (2016: £0.7m)
- Year-end cash at £4.3m (2015: £1.8m)

# **CONSOLIDATED INCOME STATEMENT**



	Note	2017	2016
		£	£
REVENUE Cost of sales Gross profit	3	4,180,630 (1,657,765) 2,522,865	3,286,147 (1,174,065) 2,112,082
Other income Administrative expenses excluding exceptional costs Exceptional administrative costs Total administrative costs	4	28,225 (5,228,211) (2,860,774) (8,060,760)	(3,897,652) (698,435) (4,596,087)
OPERATING LOSS		(5,537,895)	(2,484,005)
Finance costs LOSS BEFORE INCOME TAX		(7,833) (5,545,728)	(3,341) (2,487,346)
Income tax credit	5	127,609	73,201
LOSS ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE	E PARENT	(5,418,119)	(2,414,145)
OTHER COMPREHENSIVE INCOME Items that will or may be reclassified to profit or loss: Exchange gain/(loss) arising on translation of foreign operations OTHER COMPREHENSIVE INCOME FOR THE YEAR TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO THE	s	31,171 31,171	(6,996) (6,996)
EQUITY SHAREHOLDERS OF THE PARENT		(5,386,948)	(2,421,141)

# **SALES**



Year ended 31 December 2017	Distribution £	Direct Sales £	Total £
United Kingdom North America Rest of World	- - 1,756,115	715,531 1,708,984 -	715,531 1,708,984 1,756,115
	1,756,115	2,424,515	4,180,630
Year ended 31 December 2016	Distribution £	Direct Sales £	Total £
United Kingdom	-	1,198,457	1,198,457
North America	-	864,366	864,366
Rest of World	848,292	375,032	1,223,324
	848,292	2,437,855	3,286,147

# **CONSOLIDATED INCOME STATEMENT**



	Note	2017	2016
		£	£
REVENUE Cost of sales Gross profit	3	4,180,630 (1,657,765) 2,522,865	3,286,147 (1,174,065) 2,112,082
Other income Administrative expenses excluding exceptional costs Exceptional administrative costs Total administrative costs	4	28,225 (5,228,211) (2,860,774) (8,060,760)	(3,897,652) (698,435) (4,596,087)
OPERATING LOSS		(5,537,895)	(2,484,005)
Finance costs LOSS BEFORE INCOME TAX		(7,833) (5,545,728)	(3,341) (2,487,346)
Income tax credit	5	127,609	73,201
LOSS ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF TH	IE PARENT	(5,418,119)	(2,414,145)
OTHER COMPREHENSIVE INCOME Items that will or may be reclassified to profit or loss: Exchange gain/(loss) arising on translation of foreign operation OTHER COMPREHENSIVE INCOME FOR THE YEAR TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE PARENT	าร	31,171 31,171 (5,386,948)	(6,996) (6,996) (2,421,141)

### **OVERHEADS**



# Increase in administrative expenses excluding exceptional items:

	£m
Amortisation of intangibles arising on the acquisitions of IML and IUL	0.2
Other amortisation and depreciation increase	0.2
Increase in IML overheads (acquired 8 August 2016)	0.5
IUL overheads (acquired 6 October 2017)	0.2
Movement in exchange differences	0.1
Other	0.1
Total increase in administrative overheads excluding exceptional costs	1.3

# **CONSOLIDATED INCOME STATEMENT**



	Note	2017	2016
		£	£
REVENUE Cost of sales Gross profit	3	4,180,630 (1,657,765) 2,522,865	3,286,147 (1,174,065) 2,112,082
Other income Administrative expenses excluding exceptional costs Exceptional administrative costs Total administrative costs	4	28,225 (5,228,211) (2,860,774) (8,060,760)	(3,897,652) (698,435) (4,596,087)
OPERATING LOSS		(5,537,895)	(2,484,005)
Finance costs LOSS BEFORE INCOME TAX		(7,833) (5,545,728)	(3,341) (2,487,346)
Income tax credit	5	127,609	73,201
LOSS ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE	PARENT	(5,418,119)	(2,414,145)
OTHER COMPREHENSIVE INCOME Items that will or may be reclassified to profit or loss: Exchange gain/(loss) arising on translation of foreign operations OTHER COMPREHENSIVE INCOME FOR THE YEAR TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO THE	5	31,171 31,171	(6,996) (6,996)
EQUITY SHAREHOLDERS OF THE PARENT		(5,386,948)	(2,421,141)

# **EXCEPTIONAL ITEMS**



	2017	2016
	£	£
Goodwill impairment (see note 7)	3,328,166	-
Fair value adjustments on contingent consideration (see note	(636,628)	-
10)		
Acquisition costs	169,236	139,435
Integration costs	-	26,000
Litigation costs		533,000
	2,860,774	698,435

# **CONSOLIDATED BALANCE SHEET**



	Note	2017 £	2016 £	EQUITY CAPITAL AND RESERVES ATTRIBUTABLE	TO EQUITY HOLDE	ERS OF THE C	OMPANY	
NON CURRENT ASSETS Intangible assets Property, plant and equipment  CURRENT ASSETS Inventories Trade and other receivables Current tax assets Cash and cash equivalents	7	3,366,477 312,506 3,678,983 413,244 1,709,436 - 4,250,198 6,372,878	3,572,284 366,541 3,938,825 482,338 1,614,538 45,534 1,765,863 3,908,273	Ordinary share capital Share premium Accumulated losses Share-based payment reserve Merger reserve Foreign exchange reserve TOTAL EQUITY		(12	2,216,670 7,2 2,423,931) (7,01 413,600 3 6,013,065 3,9 20,191 (	318,986 267,139 05,812) 321,600 343,675 10,980) 334,608
TOTAL ASSETS		10,051,861	7,847,098		No	2017	No	2016
CURRENT LIABILITIES Trade and other payables	8	(2,356,702)	(2,635,327)	Ordinary share capital	No. Unlimited	± Unlimited	No. I Unlimited	± Unlimited
Provisions		(80,555) (2,437,257)	(72,830) (2,708,157)		Uliilliiteu	Omminice	I Offinitied	Offillitiited
NON CURRENT LIABILITIES				Allotted, issued and fully paid Ordinary shares of 1p each				
Deferred taxation		(467,994)	(304,333)	Balance at 1 January Shares issued for cash	31,898,576 44,125,324	318,986 441,253	, ,	201,363 71,111
TOTAL LIABILITIES		(2,905,251)	(3,012,490)	Shares issued on acquisition of IML	2,325,582	23,256	4,651,164	46,512
NET ASSETS		7,146,610	4,834,608	Shares issued on acquisition of IUL Balance at 31 December	12,351,961 90,701,443	123,520 907,015		318,986

# **ACQUISITION OF INTELLIGENT ULTRASOUND LIMITED**



	Fair Value
	£
Intangible assets	1,388,000
Property and equipment	6,763
Prepayments and other debtors	33,547
Bank and cash	1,559
Trade and other payables	(189,999)
Deferred tax	(235,960)
Net assets acquired	1,003,910
Goodwill	2,035,784
Total consideration	3,039,694
Satisfied by:	
Cash	72,000
Fair value of shares and warrants issued in the Company	1,978,463
Fair value of shares and warrants to be issued in the Company	989,231
	3,039,694

# **INTANGIBLE FIXED ASSETS**




Costs licences) £ £ £ £ £	£
COST	
	,011,325
	472,452
Acquisition of IML 1,292,382 1,650,000 133,000 3,000	,075,382
As at 31 December 2016 1,292,382 1,650,000 133,000 1,458,777 25,000 4,5	,559,159
Additions 492,118 - 4	492,118
Acquisition of IUL 2,035,784 1,388,000 3,4	,423,784
As at 31 December 2017 3,328,166 3,038,000 133,000 1,950,895 25,000 8,4	,475,061
AMORTISATION	
	577,985
	408,890
	986,875
· · · · · · · · · · · · · · · · · · · ·	793,543
	,328,166
· · · · · · · · · · · · · · · · · · ·	5,108,584
NET BOOK VALUE	77
	,366,477
	5,572,284
	433,340

# **CONSOLIDATED CASH FLOW**



	2017 £	2016 £		2017 f	2016 £
CASH FLOW FROM CONTINUING OPERATING ACTIVITIE	:S			2	_
Loss before tax	(5,545,728)	(2,487,346)	NET CASH USED IN OPERATING ACTIVITIES	(2,195,656)	(2,187,494)
Depreciation	232,369	154,123		(=/===/===/	(=/==:/:=:/
Amortisation of intangible assets	793,543	408,890	CASH FLOWS FROM INVESTING ACTIVITIES		
Impairment of goodwill	3,328,166	-	Purchase of property, plant and equipment	(183,012)	(156,800)
Fair value adjustment on contingent consideration	(636,628)	-	Disposal of property, plant and equipment	11,440	16,209
Finance costs/(income)	7,833	3,341	Internally generated intangible assets	(492,118)	(472,452)
Share-based payments	92,000	70,600	Cash used on acquisition of subsidiaries	(72,000)	-
Operating cash flows before movement in working			Cash acquired on acquisition of subsidiaries	1,559	272,787
capital	(1,728,445)	(1,850,392)	NET CASH USED IN INVESTING ACTIVITIES	(734,131)	(340,256)
Movement in inventories	69,094	(82,913)	CACLLELOWIC FROM FINANCING ACTIVITIES		
Movement in trade and other receivables	(61,351)	(350,911)	CASH FLOWS FROM FINANCING ACTIVITIES Issue of new shares	E E1E 66E	2 200 000
Movement in trade and other payables	(575,798)	96,722	Share issue costs	5,515,665 (124,881)	3,200,000 (183,817)
	(0.07.00)		Finance (costs paid)/income received	(7,833)	(3,341)
Cash used in operations	(2,296,500)	(2,187,494)	NET CASH GENERATED FROM FINANCING ACTIVITIES	5,382,951	3,012,842
	(=,===,===,	(=/==:/:=:/	Exchange gains/(losses) on cash and cash equivalents	31,171	(6,996)
Income taxes received	100,844	-	Exchange gains/(1055e5) on cash and cash equivalents		(0,990)
NET CASH USED IN OPERATING ACTIVITIES	(2,195,656)	(2,187,494)			
			NET INCREASE IN CASH AND CASH EQUIVALENTS	2,484,335	478,096
			CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	1,765,863	1,287,767
			CASH AND CASH EQUIVALENTS AT END OF YEAR	4,250,198	1,765,863





unlocking the potential of ultrasound